Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.72B | 1.60B | 1.38B | 1.22B | 1.07B |
Gross Profit | 459.01M | 418.29M | 359.01M | 336.97M | 285.71M |
EBITDA | 310.91M | 256.51M | 215.40M | 215.26M | 207.56M |
Net Income | 119.90M | 90.65M | 66.38M | 96.81M | 77.26M |
Balance Sheet | |||||
Total Assets | 3.08B | 2.94B | 2.79B | 2.58B | 2.37B |
Cash, Cash Equivalents and Short-Term Investments | 46.54M | 23.67M | 24.27M | 17.89M | 49.21M |
Total Debt | 1.10B | 1.05B | 1.01B | 897.75M | 777.55M |
Total Liabilities | 1.46B | 1.42B | 1.38B | 1.23B | 1.10B |
Stockholders Equity | 1.62B | 1.52B | 1.42B | 1.35B | 1.27B |
Cash Flow | |||||
Free Cash Flow | 99.60M | 60.27M | 41.65M | 103.20M | 129.90M |
Operating Cash Flow | 205.21M | 180.21M | 116.38M | 156.67M | 181.34M |
Investing Cash Flow | -195.41M | -163.37M | -200.42M | -271.00M | -56.58M |
Financing Cash Flow | 13.32M | -18.01M | 92.48M | 81.99M | -88.58M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $3.72B | 58.11 | 8.07% | ― | 27.11% | ― | |
66 Neutral | $5.30B | ― | -91.13% | ― | 22.37% | 31.14% | |
65 Neutral | $3.77B | 47.57 | 5.15% | ― | 7.21% | -23.29% | |
56 Neutral | $0.00 | 30.62 | -19.69% | ― | 7.97% | -592.40% | |
51 Neutral | $7.38B | 0.52 | -67.26% | 2.36% | 16.67% | -0.20% | |
50 Neutral | $2.76B | ― | -27.62% | ― | 59.36% | 19.87% | |
48 Neutral | $0.00 | ― | -12.98% | ― | 26.70% | 48.19% |
Integer Holdings Corporation reported strong financial results for the second quarter of 2025, with sales increasing by 11% to $476 million and adjusted operating income rising by 15% to $81 million compared to the same period in 2024. The company also raised its full-year profit outlook, expecting adjusted operating income growth of 12% to 16% and adjusted EPS growth of 18% to 23%, driven by robust sales in cardio and vascular segments and strategic acquisitions.
The most recent analyst rating on (ITGR) stock is a Buy with a $152.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.
On July 10, 2025, Integer Holdings Corporation announced the election of Michael J. Coyle to its Board of Directors, expanding the board to 11 members. Coyle, with over 40 years of leadership experience in the medical device industry, will serve on several committees and contribute to Integer’s strategic initiatives and growth. His extensive background, including roles at iRhythm Technologies and Medtronic, is expected to bolster Integer’s position as a partner of choice for innovative medical technologies, enhancing its contract development and manufacturing outsourcing strategy.
The most recent analyst rating on (ITGR) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.
On July 2, 2025, Integer Holdings Corporation announced that its 2.125% Convertible Senior Notes due 2028 are now convertible at the holders’ option during the calendar quarter ending September 30, 2025. This conversion option was triggered as the company’s stock price exceeded 130% of the conversion price for at least 20 trading days in a 30-day period ending June 30, 2025. The notes can be converted into cash, shares of common stock, or a combination thereof, depending on the company’s choice. This announcement could impact the company’s financial strategy and market positioning, as it allows note holders to convert their notes into equity, potentially affecting the company’s stock liquidity and capital structure.
The most recent analyst rating on (ITGR) stock is a Buy with a $152.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.
At the Annual Meeting on May 21, 2025, Integer Holdings‘ stockholders approved several key proposals. These included the election of ten directors for a one-year term, the ratification of Deloitte & Touche LLP as the independent auditors for fiscal year 2025, approval of executive compensation on an advisory basis, and an amendment to the company’s Restated Certificate of Incorporation to include an officer exculpation provision. These decisions are expected to impact the company’s governance and operational strategies moving forward.
The most recent analyst rating on (ITGR) stock is a Buy with a $152.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.